Skip to main content
Clinical Trials/ChiCTR1900022538
ChiCTR1900022538Not yet recruitingPhase 4

胃癌术后化疗同时予以益生菌治疗效果研究

自筹1 site in 1 country150 target enrollmentStarted: June 1, 2019Last updated:

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor
Enrollment
150
Locations
1
Primary Endpoint
粪便高通量测序

Study Overview

Brief Summary

通过口服益生菌恢复胃癌胃切除术后化疗导致的胃肠道功能失常,帮助恢复肠道微生物多样性,增加优势菌群浓度,预防或缓解胃癌术后化疗并发症,恢复胃肠道功能。

Study Design

Study Type
干预性研究
Primary Purpose
随机平行对照
Masking
None

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1、知情同意者;2、病理确诊为胃癌,胃切除术后;3、患者一般情况良好,年龄 18-70 岁。

Exclusion Criteria

  • 1、患者合并有严重的心、肺、肾、肝功能障碍及代谢性疾病;2、对益生菌过敏者; 3、有免疫疾病、不能口服或吸收消化道药物或对益生菌过敏者。

Arms & Interventions

Group 2

术后化疗+培菲康益生菌制剂

Group 1

单纯术后化疗

Outcomes

Primary Outcomes

粪便高通量测序

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
自筹

Study Sites (1)

Loading locations...

Similar Trials